Saroglitazar for the treatment of dyslipidemia in diabetic patients.
作者： Shashank R Joshi
DOI: 10.1517/14656566.2015.1009894
关键词:
摘要: Introduction: Diabetes and dyslipidemia are commonly associated modifiable risk factors for cardiovascular diseases. Majority of patients with diabetes also suffer from (diabetic dyslipidemia). Diabetic is more atherogenic as it high triglyceride (TG) levels, proportion small dense low-density lipoprotein cholesterol low high-density (HDL-C) level (atherogenic Currently used pharmacotherapies the management like thiazolidinediones (PPAR-γ agonist; insulin resistance) fibrates (PPAR-α hypertriglyceridemia) have many limitations side effects. Saroglitazar, a dual PPAR-α/γ agonists, an emerging therapeutic option its benefit on glycemic lipid parameters.Areas covered: This paper reviews clinical development saroglitazar diabetic dyslipidemia. The efficacy safety profile reviewed i...
sci-hub.se 参考文章(58)
Dariush Mozaffarian, Jason H.Y. Wu, Omega-3 Fatty Acids and Cardiovascular Disease Journal of the American College of Cardiology. ,vol. 58, pp. 2047- 2067 ,(2011) , 10.1016/J.JACC.2011.06.063
MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. The Lancet. ,vol. 361, pp. 2005- 2016 ,(2003) , 10.1016/S0140-6736(03)13636-7
Combination lipid therapy in type 2 diabetes. The New England Journal of Medicine. ,vol. 363, pp. 692- 695 ,(2010) , 10.1056/NEJMC1006407
ORIGIN Trial Investigators, None, n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. The New England Journal of Medicine. ,vol. 367, pp. 309- 318 ,(2012) , 10.1056/NEJMOA1203859
Alan D. Lopez, Christopher J. L. Murray, The global burden of disease: a comprehensive assessment of mortality and disability from diseases injuries and risk factors in 1990 and projected to 2020. Harvard School of Public Health on behalf of the World Health Organization and the World Bank , Distributed by Harvard University Press. ,(1996)
L. A. Leiter, P. Lundman, P. M. da Silva, H. Drexel, C. Jünger, A. K. Gitt, , Persistent lipid abnormalities in statin-treated patients with diabetes mellitus in Europe and Canada: results of the Dyslipidaemia International Study Diabetic Medicine. ,vol. 28, pp. 1343- 1351 ,(2011) , 10.1111/J.1464-5491.2011.03360.X
Gualberto Ruaño, James Bernene, Andreas Windemuth, Bruce Bower, Detlef Wencker, Richard L. Seip, Mohan Kocherla, Theodore R. Holford, William A. Petit, Steven Hanks, Physiogenomic comparison of edema and BMI in patients receiving rosiglitazone or pioglitazone. Clinica Chimica Acta. ,vol. 400, pp. 48- 55 ,(2009) , 10.1016/J.CCA.2008.10.009
Pascal Escher, Olivier Braissant, Sharmila Basu-Modak, Liliane Michalik, Walter Wahli, Béatrice Desvergne, Rat PPARs: quantitative analysis in adult rat tissues and regulation in fasting and refeeding. Endocrinology. ,vol. 142, pp. 4195- 4202 ,(2001) , 10.1210/ENDO.142.10.8458
, Z. Reiner, A. L. Catapano, G. De Backer, I. Graham, M.-R. Taskinen, O. Wiklund, S. Agewall, E. Alegria, M. J. Chapman, P. Durrington, S. Erdine, J. Halcox, R. Hobbs, J. Kjekshus, P. P. Filardi, G. Riccardi, R. F. Storey, D. Wood, J. Bax, A. Vahanian, A. Auricchio, H. Baumgartner, C. Ceconi, V. Dean, C. Deaton, R. Fagard, G. Filippatos, C. Funck-Brentano, D. Hasdai, R. Hobbs, A. Hoes, P. Kearney, J. Knuuti, P. Kolh, T. McDonagh, C. Moulin, D. Poldermans, B. A. Popescu, Z. Reiner, U. Sechtem, P. A. Sirnes, M. Tendera, A. Torbicki, P. Vardas, P. Widimsky, S. Windecker, D. Reviewers:, C. Funck-Brentano, D. Poldermans, G. Berkenboom, J. De Graaf, O. Descamps, N. Gotcheva, K. Griffith, G. F. Guida, S. Gulec, Y. Henkin, K. Huber, Y. A. Kesaniemi, J. Lekakis, A. J. Manolis, P. Marques-Vidal, L. Masana, J. McMurray, M. Mendes, Z. Pagava, T. Pedersen, E. Prescott, Q. Rato, G. Rosano, S. Sans, A. Stalenhoef, L. Tokgozoglu, M. Viigimaa, M. E. Wittekoek, J. L. Zamorano, , , ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)☆☆☆ Atherosclerosis. ,vol. 32, pp. 1769- 1818 ,(2011) , 10.1093/EURHEARTJ/EHR158